Hvor det er relevant, bør samtidig behandling med en protonpumpehæmmer overvejes. • Patienter med klinisk signifikant infektion, som kræver behandling med antibiotika, antimykotika eller antivirale midler, eller patienter, som inden for 14 dage før initiering af behandling har gennemgået behandling mod infektion, bør behandles med forsigtighed, medmindre brugen af antibiotika og antivirale midler havde profylaktiske formål. • Patienter, der tidligere har haft en autoimmun sygdom i anamnesen (såsom systemisk lupus, inflammatorisk tarmsygdom, psoriasis og rheumatoid artritis) bør behandles med forsigtighed. • Monitorering af laboratorieprøveresultater anbefales, herunder standard hæmatologiske analyser og blodkemiprøver. • Patienter, som får følgende lægemidler, bør behandles med forsigtighed (se punkt 4. 5)
Where appropriate, consideration should be made to providing concomitant treatment with a proton pump inhibitor. • Patients with clinically significant infection requiring the use of antibiotics, antifungals, or antivirals, or who have completed prior anti-infectious therapy within 14 days of starting treatment should be treated with caution unless the use of antibiotics and antivirals were for prophylaxis purposes. • Patients with a prior history of autoimmune disease (including systemic lupus, inflammatory bowel disease, psoriasis and rheumatoid arthritis) should be treated with caution. • Monitoring of laboratory test results is recommended including standard haematological and blood chemistry tests. • Patients receiving the following medicinal products should be treated with caution (see section 4.5) -Beta-blockers or other anti-hypertensive agents. -H1 blocking agents and neuroleptics (anti-psychotics) with H1 receptor blocking properties. -Tricyclic anti-depressants that may have H1 and H2 receptor blocking properties. -Monoamine oxidase inhibitors and anti-malarial and anti-trypanosomal agents. -Neuromuscular blocking agents, narcotic analgesics, and various contrast media.